Kyorin & Cyrano Therapeutics Option Agreement for CYR-064 in Japan
18 Feb 2025 //
PR NEWSWIRE
Cyrano Launch Study on CYR-064 for Hyposmia in Parkinson’s Disease
04 Feb 2025 //
PR NEWSWIRE
Cyrano Therapeutics Secures $9.0 Million Series B Financing
16 Jan 2024 //
PR NEWSWIRE
Cyrano Therapeutics Enrolls First Patient in Phase 2 Trial of CYR-064
12 Oct 2023 //
PR NEWSWIRE
Cyrano to initiate Phase II trial of nasal spray therapy for Hyposmia
19 Jan 2023 //
CLINICAL TRIALS ARENA
Cyrano Appoints John Kollins to its Board of Directors
09 Nov 2021 //
PRNEWSWIRE